The world is talking about ending AIDS. AVAC’s advocacy is dedicated to realizing that vision. To get there we must:
Is HIV prevention research seeing its last placebo-controlled efficacy trials? Will the field have to radically reimagine how to answer efficacy questions?
As 2018 comes to an end, AVAC extends gratitude to all HIV prevention advocates—those we work with, those whose names we do not know—for the hope and fierce commitment that you bring to the work every day.
In this episode of Px Pulse, we consider how future HIV prevention trials will need to be designed as HIV prevention evolves... and how to strengthen community engagement along with it. At the heart of the matter is that clinical trials for HIV prevention are set to get bigger and more complex, in response to advances in HIV prevention, such as PrEP.
As 2018 winds down, we’re struck by the many moments, and movements, in the past year that have depended on listening, without bias and also without loss of conviction. In that spirit, our year-end edition of Px Wire offers 10 questions for activists to pose, with curiosity and conviction, in 2019. What answers do you want, what do you hear, what needs to happen next?
AVAC has an extensive online resource library with hundreds of Reports, Publications, Infographics & more. And it includes powerful search features to find exactly what you’re looking for.
AVAC uses education, policy analysis, advocacy, community mobilization and a network of global collaborations to accelerate ethical development and global delivery of biomedical HIV prevention options. Read more
AVAC advocates for a comprehensive response to the epidemic, involving smart use of every proven HIV prevention option available today and sustained research into many new strategies.